Accès gratuit
Numéro
Med Sci (Paris)
Volume 20, Numéro 5, Mai 2004
Page(s) 562 - 568
Section SYNTHÈSE
DOI https://doi.org/10.1051/medsci/2004205562
Publié en ligne 15 mai 2004
  1. http://www-dep.iarc.fr, 2000.
  2. Labrie F, Candas B, Dupont A, et al. Screening decreases prostate cancer death : First analysis of the 1988 Quebec prospective randomized controlled trial. Prostate 1999; 38 : 83–91.
  3. Cussenot O, Valeri A. Heterogeneity in genetic susceptibility to prostate cancer. Eur J Intern Med 2001; 12 : 11–6.
  4. Cussenot O, Fournier G. Génétique et urologie. Paris : les Éditions Vingt et un. Progrès en Urologie 2000 : 417p.
  5. Morganti G, Gianferrari L, Cresseri A, et al. Recherches clinico-statistiques et génétiques sur les néoplasies de la prostate. Acta Genet Stat Med 1956; 6 : 304–5.
  6. Grönberg H, Damber L, Damber JE. Studies of genetic factors in prostate cancer in twin population. J Urol 1994; 152 : 1484–9.
  7. Schaid DJ, McDonnell SK, Blute ML, et al. Evidence for autosomal dominant inheritance of prostate cancer. Am J Hum Genet 1998; 62 : 1425–38.
  8. Carter BS, Beaty TH, Steinberg GD, et al. Mendelian inheritance of familial prostate cancer. Proc Natl Acad Sci USA 1992; 89 : 3367–71.
  9. Xu J and the International consortium for prostate cancer genetics. Combined analysis of hereditary prostate cancer linkage to 1q24-25 : results from 772 hereditary prostate cancer families from the International consortium for prostate cancer genetics. Am J Hum Genet 2000; 66 : 945–57.
  10. Berthon P, Valeri A, Cohen-Akenine A, et al. Predisposing gene for early-onset prostate cancer, localized on chromosome 1q42.2-43. Am J Hum Genet 1998; 62 : 1416–24.
  11. Cancel-Tassin G, Latil A, Valeri A, et al. PCAP is the major known prostate cancer predisposing locus in families from south and west Europe. Eur J Hum Genet 2001; 9 : 135–42.
  12. Karayi MK, Neal DE, Markham AF. Current status of linkage studies in hereditary prostate cancer. BJU Int 2000; 86 : 659–69.
  13. Valeri A, Azzouzi R, Drelon E, et al. Early-onset hereditary prostate cancer is not associated with specific clinical biological features. Prostate 2000; 45 : 66–71.
  14. Goode EL, Stanford JL, Peters MA, et al. Clinical characteristics of prostate cancer in an analysis of linkage to four putative susceptibility loci. Clin Cancer Res 2001; 7 : 2739–49.
  15. Bratt O. Hereditary prostate cancer : Clinical aspects. J Urol 2002; 168 : 906–13.
  16. Valeri A, Fournier G, Morin V, et al. Early onset and familial predisposition to prostate cancer significantly enhance the probability for breast cancer in first degree relatives. Int J Cancer 2000; 86 : 883–7.
  17. Edwards SM, Kote-Jarai Z, Meitz J, et al. Two percent of men with early-onset prostate cancer harbor germline mutations in the BRCA2 gene. Am J Hum Genet 2003; 72 : 1–12.
  18. Gayther SA, de Foy KA, Harrington P, et al. The frequency of germ-line mutations in the breast cancer predisposition genes BRCA1 and BRCA2 in familial prostate cancer. The cancer research campaign/British prostate group united kingdom familial prostate cancer study collaborators. Cancer Res 2000; 60 : 4513–8.
  19. Jonsson BA, Bergh A, Stattin P, et al. Germline mutations in E-cadherin do not explain association of hereditary prostate cancer, gastric cancer and breast cancer. Int J Cancer 2002; 98 : 838–43.
  20. Ross RK, Pike MC, Coetzee GA, et al. Androgen metabolism and prostate cancer : Establishing a model of genetic susceptibility. Cancer Res 1998; 58 : 4497–504.
  21. Bosland MC. The role of steroid hormones in prostate carcinogenesis. J Natl Cancer Inst Monogr 2000; 27 : 39–66.
  22. Irvine RA, Yu MC, Ross RK, et al. The CAG and GGC microsatellites of the androgen receptor gene are in linkage disequilibrium in men with prostate cancer. Cancer Res 1995; 55 : 1937–40.
  23. Edwards A, Hammond HA, Jin L, et al. Genetic variation at five trimeric and tetrameric tandem repeat loci in four human population groups. Genomics 1992; 12 : 241–53.
  24. Rebbeck TR, Jaffe JM, Walker AH, et al. Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. J Natl Cancer Inst 1998; 90 : 1225–9.
  25. Lunn RM, Bell DA, Mohler JL, et al. Prostate cancer risk and polymorphism in 17 hydroxylase (CYP17) and steroid reductase (SRD5A2). Carcinogenesis 1999; 20 : 1727–31.
  26. Chang BL, Zheng SL, Hawkins GA, et al. Joint effect of HSD3B1 and HSD3B2 genes is associated with hereditary and sporadic prostate cancer susceptibility. Cancer Res 2002; 62 : 1784–9
  27. Latil A, Azzouzi R, Cancel G, et al. Prostate carcinoma risk and allelic variants of genes involved in androgen biosynthesis and metabolism pathways. Cancer 2001; 92 : 1130–7.
  28. Cancel-Tassin G, Latil A, Rousseau F, et al. Association study of polymorphisms in the human estrogen receptor alpha gene and prostate cancer risk. Eur Urol 2003; 44 : 487–90.
  29. Tang YM, Green BL, Chen GF, et al. Human CYP1B1 Leu432Val gene polymorphism : ethnic distribution in African-Americans, Caucasians and Chinese ; oestradiol hydroxylase activity ; and distribution in prostate cancer cases and controls. Pharmacogenetics 2000; 10 : 761–6.
  30. Correa-Cerro L, Berthon P, Haussler J, et al. Vitamin D receptor polymorphisms as markers in prostate cancer. Human Genet 1999; 105 : 281–7.
  31. Reszka E, Wasowicz W. Genetic polymorphism of N-acetyltransferase and glutathione S-transferase related to neoplasm of genitourinary system. Neoplasma 2002; 49 : 209–16.
  32. Simard J, Dumont M, Soucy P, et al. Perspective : prostate cancer susceptibility genes. Endocrinology 2002; 143 : 2029–40.
  33. Nwosu V, Carpten J, Trent JM, et al. Heterogeneity of genetic alterations in prostate cancer : Evidence of the complex nature of the disease. Hum Mol Genet 2001; 10 : 2313–8.
  34. Valeri A, Cormier L, Moineau MP, et al. Targeted screening for prostate cancer in high risk families : Early onset is a significant risk factor for disease in first degree relatives. J Urol 2002; 168 : 483–7.
  35. Novelli G, Margiotti K, Sangiuolo F, et al. Pharmacogenetics of human androgens and prostatic diseases. Pharmacogenomics 2001; 2 : 65–72.

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.